Phaseline

Targets › IGF1R

IGF1R (Insulin-like growth factor 1 receptor): drug programs, companies and trials

14 programs from 12 companies in 27 trials: 13 Phase 3, 6 Phase 2, 4 Phase 1, 4 Phase 4; Ophthalmology, Oncology, Cardiovascular; next expected readout Nov 2026.

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. (UniProt, P08069)

Open in Phaseline: the race on IGF1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Innovent Biologics (Suzhou)Teprotumumab (N01)
Insulin-like growth factor I receptor antagonist
IGF1RPhase 4Thyroid Eye DiseaseJun 2028
AmgenTeprotumumab
Insulin-like growth factor I receptor antagonist
IGF1RPhase 3Thyroid Eye DiseaseNov 2026
Viridian TherapeuticsVRDN-003
Humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-
IGF1RPhase 3Thyroid Eye Disease (TED); Thyroid Eye DiseaseNov 2026
Minghui Pharmaceutical (Hangzhou)MHB018A
Humanized anti-IGF1R antibody
IGF1RPhase 3Thyroid Associated Ophthalmopathies; Thyroid Eye Disease (TED); Thyroid Eye Disease, TEDDec 2026
Innovent Biologics (Suzhou)IBI311
IGF-1 receptor antagonist
IGF1RPhase 3Thyroid Eye Disease; Thyroid Associated OphthalmopathiesDec 2026
Zai Lab (Shanghai)ZL-1109 (VRDN-003)
IGF-1 receptor antagonist
IGF1RPhase 3Thyroid Eye Disease (TED)Mar 2027
National Cancer Institute (NCI)Ganitumab
Insulin-like growth factor I receptor antagonist
IGF1RPhase 3Metastatic Ewing SarcomaSep 2027
Sling Therapeuticslinsitinib
Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor
IGF1R, INSRPhase 3Thyroid Eye Disease, TED; Thyroid Eye DiseaseJun 2028
University of WashingtonpUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC)
Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate
IGFBP2, HER2, IGF1RPhase 2Anatomic Stage I Breast Cancer AJCC v8Dec 2026
National Cancer Institute (NCI)Cixutumumab
Insulin-like growth factor I receptor antagonist
IGF1RPhase 2Metastatic Esophageal AdenocarcinomaMar 2027
H. Lee Moffitt Cancer Center and Research InstituteWOKVAC
pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R
IGFBP2, ERBB2, IGF1RPhase 2Breast Cancer FemaleDec 2027
OHB NeonatologyMecasermin Rinfabate (OHB-607)
Insulin-like growth factor I receptor agonist
IGF1RPhase 2Bronchopulmonary DysplasiaJan 2028
QuantumLeap Healthcare CollaborativeGanitumab
Insulin-like growth factor I receptor antagonist
IGF1RPhase 2Breast NeoplasmsDec 2030
Candid TherapeuticsCizutamig (CND106)
IGF-1 receptor antagonist
IGF1RPhase 1Generalized Myasthenia Gravis; Systemic Lupus Erythematosus (SLE); Thyroid Eye Disease, TED; Rheumatoid Arthritis (RA)Dec 2027

Conditions

Thyroid Eye Disease (6) Thyroid Eye Disease, TED (4) Thyroid Eye Disease (TED) (4) Thyroid Associated Ophthalmopathies (4) Bronchopulmonary Dysplasia (1) Generalized Myasthenia Gravis (1) Systemic Lupus Erythematosus (SLE) (1) Rheumatoid Arthritis (RA) (1) Metastatic Ewing Sarcoma (1) Breast Neoplasms (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Breast Cancer Female (1)

Modalities

small molecule (5), mixed (5), antibody (2), protein or peptide (1), other (1)

Companies

Innovent Biologics (Suzhou) (2) National Cancer Institute (NCI) (2) OHB Neonatology (1) Amgen (1) Candid Therapeutics (1) Viridian Therapeutics (1) Minghui Pharmaceutical (Hangzhou) (1) Sling Therapeutics (1) QuantumLeap Healthcare Collaborative (1) Zai Lab (Shanghai) (1) University of Washington (1) H. Lee Moffitt Cancer Center and Research Institute (1)

Related targets

IGFBP2 (2) INSR (1) HER2 (1) ERBB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.